Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Chest X-ray of a congestive heart failure patient, showing fluid in the lower portions of the lungs and an enlarged heart. Getty Images

Chest X-ray of a congestive heart failure patient, showing fluid in the lower portions of the lungs and an enlarged heart. Getty Images

News | Heart Failure | October 05, 2020
October 5, 2020 — The American College of Cardiology (ACC) says heart failure (HF) is a cardiovascular epidemic. In...
The Latest Vascular Interventional Clinical Data Presented at VIVA 2020 late-breaking sessions
News | VIVA | October 05, 2020
October 5, 2020 — The Vascular Interventional Advances (VIVA) virtual conference will feature 10 late-breaking clinical...
Very ill COVID-19 patients have a high rate of in-hospital sudden cardiac arrest and a very low survival rate.

Very ill COVID-19 patients have a high rate of in-hospital sudden cardiac arrest and very low survival rates. Getty Images

Feature | Coronavirus (COVID-19) | October 02, 2020
October 2, 2020 — Even when a sudden cardiac arrest happens inside a top hospital, where a code blue team is readily...
An example of a CT coronary artery calcium scoring exam showing how each vessel segment is scored to assess a patient's risk for a future heart attack. Example is from Philips Healthcare.

An example of a CT coronary artery calcium scoring exam showing how each vessel segment is scored to assess a patient's risk for a future heart attack. Example is from Philips Healthcare.

News | Cardiac Imaging | September 25, 2020
September 25, 2020 — A study out of University Hospitals (UH) found that removing the cost barrier for coronary artery...
SARS-CoV-2 infection of cells shown in green, left. This is inhibited by a modified form of cholesterol called 25-hydroxycholesterol (25HC), as seen in the cells in the right image. 25HC activates an enzyme called ACAT, found inside cells in the endoplasmic reticulum. ACAT then depletes accessible cholesterol on the cell’s membrane. It is a normally occurring process that gets kicked into high gear during some viral infections. Image from UC San Diego Health Sciences.

SARS-CoV-2 infection of cells shown in green, left. This is inhibited by a modified form of cholesterol called 25-hydroxycholesterol (25HC), as seen in the cells in the right image. 25HC activates an enzyme called ACAT, found inside cells in the endoplasmic reticulum. ACAT then depletes accessible cholesterol on the cell’s membrane. It is a normally occurring process that gets kicked into high gear during some viral infections. Image from UC San Diego Health Sciences.

News | Coronavirus (COVID-19) | September 24, 2020
September 24, 2020 — Analyzing anonymized patient medical records, University of California (UC) San Diego Health...
TCT 2020 Late-breaking Study trial Presentations Announced. #TCTconnect #TCT2020 #TCT
Feature | TCT | October 29, 2020
October 29, 2020 — The late-breaking studies are one of the hallmarks of the annual Transcatheter Cardiovascular...
The NIH is heading three studies looking at various blood thinners and anticoagulants to treat COVID-19 patients with VTE.
News | Coronavirus (COVID-19) | September 11, 2020
September 11, 2020 — The National Institutes of Health (NIH) has launched two of three adaptive clinical trials...
Medtronic announced U.S. Food and Drug Administration (FDA) approval of an early feasibility study (EFS) of the Intrepid Transcatheter Tricuspid Valve Replacement (TTVR) system. The study begins on the heels of a recent Breakthrough Device Designation issued by the FDA for the Intrepid TTVR System. The Intrepid TTVR system is an investigational device worldwide.
News | Heart Valve Technology | September 11, 2020
September 11, 2020 – Medtronic announced U.S. Food and Drug Administration (FDA) approval of an early feasibility study...
Videos | Pharmaceuticals | September 10, 2020
Matthew Budoff, M.D., director of cardiovascular CT at The Lundquist Institute, and professor of medicine at the David...
Icosapent ethyl (Vascepa) demonstrated significant, 17 percent regression of low attenuation plaque (LAP) volume on multidetector computed tomography (MDCT) compared with placebo over 18 months in the EVAPORATE Trial
News | Pharmaceuticals | September 10, 2020
September 10, 2020 - Icosapent ethyl (Vascepa) demonstrated significant, 17 percent regression of low attenuation...
The Opimax TiNO bio-active coated stent made by Hexacath.

The Opimax TiNO bio-active coated stent made by Hexacath.

News | September 10, 2020
September 5, 2020 – The TIDES-ACS Randomized Controlled Trial results were published end of July 2020 confirming the...
Biotronik's closed loop stimulation (CLS) technology helps reduce unexplained fainting in patients with recurrent episodes due to skipped heartbeats. #ESC2020
News | EP Lab | September 08, 2020
September 8, 2020 - A new study presented at the 2020 European Society of Cardiology (ESC) Congress shows that...
The BRACE CORONA trial presented at ESC Congress 2020 is the First Randomized Trial Backs Safety of ACE and ARB Heart Drugs in COVID-19 Patients.
News | Coronavirus (COVID-19) | September 08, 2020
September 8, 2020 - Heart patients hospitalized with COVID-19 (SARS-CoV-2) can safely continue taking angiotensin-...
Abbott Espirit BTK Bioresorbable stent, or bioresorbable vascular scaffold (BVS) measures 99 microns and is made from poly-L-lactide (PLLA), a semi-crystalline bioresorbable polymer engineered to resist vessel recoil and provide a platform for drug delivery. Abbott Absorb

Abbott Espirit BTK Bioresorbable stent, or bioresorbable vascular scaffold (BVS) measures 99 microns and is made from poly-L-lactide (PLLA), a semi-crystalline bioresorbable polymer engineered to resist vessel recoil and provide a platform for drug delivery.

Feature | Stents Bioresorbable | September 03, 2020
September 3, 2020 — Abbott today announced the start of the LIFE-BTK clinical trial to evaluate the safety and...
Tailor PCI trial showed genetic testing may play a role in personalizing antiplatelet therapy after PCI.
News | Antiplatelet and Anticoagulation Therapies | September 02, 2020
September 2, 2020 — An international, first-of-its-kind cardiology trial used personalized genetic testing to reduce by...